• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT VASCULAR ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE SCAFFOLD

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT VASCULAR ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE SCAFFOLD Back to Search Results
Catalog Number 1012462-18
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 02/01/2017
Event Type  Injury  
Manufacturer Narrative
Date of event: estimated.Date of implant: estimated.The device was not returned for analysis.A review of the lot history record and complaint history could not be conducted because the lot number was not provided.The reported patient effects/treatments are consistent with the product risk profile and are therefore expected.A conclusive cause for the difficulties listed can not be determined based on the limited information available.Based on the information reviewed, there is no indication of a product quality issue with respect to manufacture, design or labeling literature article title "one-year results following a pre-specified absorb implantation strategy in st-elevation myocardial infarction (bvs stemi strategyit study)".The other events reported in the article are filed under separate mfr report numbers.
 
Event Description
It was reported through a research article identifying the absorb bioresorbable vascular scaffold (bvs).Pre-dilatation was not performed in the lesion located in the mid left anterior descending coronary artery (mlad).A 2.5 x 18 mm absorb scaffold was implanted but not post dilated.Five months post scaffold implantion, target lesion revascularization was performed and another drug eluting stent bioresorbable scaffold was implanted as treatment.Details are listed in the article, titled "one-year results following a pre-specified absorb implantation strategy in st-elevation myocardial infarction (bvs stemi strategy-it study)".Specifically, this complaint was created to capture patient 5 in table 3.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ABSORB BIORESORBABLE VASCULAR SCAFFOLD SYSTEM
Type of Device
BIORESORBABLE SCAFFOLD
Manufacturer (Section D)
ABBOTT VASCULAR
26531 ynez rd.
temecula CA 92591 4628
Manufacturer (Section G)
ABBOTT VASCULAR, REG # 2024168
26531 ynez road
temecula CA 92591 4628
Manufacturer Contact
lindsey bell
26531 ynez rd.
temecula, CA 92591-4628
9519143996
MDR Report Key10817685
MDR Text Key215545261
Report Number2024168-2020-09380
Device Sequence Number1
Product Code PNY
Combination Product (y/n)Y
Reporter Country CodeIT
PMA/PMN Number
P150023
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,l
Reporter Occupation Physician
Type of Report Initial
Report Date 11/10/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue Number1012462-18
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 10/21/2020
Initial Date FDA Received11/10/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age55 YR
-
-